Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  European Journal of Cancer

• Publication date

  2000-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0959-8049(99)00259-2PMID 10785604
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer.

  1998cited by this paper
• Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

  1998cited by this paper
• First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.

  1998cited by this paper
• Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

  1998cited by this paper
• Cancer statistics, 1997

  1997cited by this paper
• Ovarian ablation in early breast cancer: Overview of the randomised trials

  1996cited by this paper
• Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.

  1996cited by this paper
• Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

  1995cited by this paper
• Understanding adjuvant chemotherapy for breast cancer.

  1994cited by this paper
• Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.

  1994cited by this paper
• Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

  1989cited by this paper
• Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

  1988cited by this paper
• The importance of dose intensity in chemotherapy of metastatic breast cancer.

  1984cited by this paper

• Barriers to cure in advanced non-seminomatous germ cell tumors: a clinical audit from a resource-limited region in India.

  2026cites this paper
• The timing of surgery for elderly patients with locally advanced breast cancer

  2025cites this paper
• Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer

  2025cites this paper
• Efficacy and Safety of Pegylated Filgrastim as Primary Prophylaxis Following Pediatric Dose-intensive Chemotherapy: A Randomized Controlled Trial.

  2025cites this paper
• Leukopenia and Neutropenic Fever.

  2025cites this paper
• The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort study.

  2024cites this paper
• Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients.

  2023cites this paper
• Baseline quality of life and chemotherapy toxicities in patients with early breast cancer

  2023cites this paper
• Safety analysis of therapeutic drugs for breast cancer patients and construction of a predictive model for serious adverse drug reactions

  2023cites this paper
• Home-Based Buddhist Walking Meditation Mitigates Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients: A Randomized Controlled Trial

  2023cites this paper
• Cell cycle arrest: A breakthrough in the supportive care of older cancer patients

  2023cites this paper
• Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors

  2022cites this paper
• Delays and disruptions in breast cancer care due to coronavirus disease-2019 pandemic: Real-World data from India

  2022cites this paper
• The Impact of Chemotherapy Schedule Modification on Survival Outcome among Breast Cancer Patients Receiving Adjuvant or Neoadjuvant Treatment Modalities

  2022cites this paper
• The Impact of Virtual Cancer Care on Chemotherapy Delivery and Clinical Outcomes in Colorectal Cancer Patients Receiving Systemic Therapy: A Pre- and Intra-Pandemic Analysis

  2022cites this paper
• Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial

  2022cites this paper
• Chemotherapy limiting neutropenia. Is prevention required?

  2022cites this paper
• Effectiveness of physical exercise on the cardiovascular system in breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.

  2021cites this paper
• Infectious diseases as a cause of death among cancer patients: a trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database

  2021cites this paper
• Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

  2021cites this paper
• Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

  2021cites this paper
• Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data

  2021cites this paper
• Neutropenia in breast cancer patients receiving Paclitaxel as chemotherapy: a study in a tertiary care centre in Northeast India

  2021cites this paper
• Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy

  2020cites this paper
• Роль пролонгированных гранулоцитарных колониестимулирующих факторов в профилактике фебрильной нейтропении у пациентов, получающих двухнедельные

  2020cites this paper
• Impact of chemotherapy schedule modification on breast cancer patients: a single-centre retrospective study

  2020cites this paper
• Machine learning improves the prediction of febrile neutropenia in Korean inpatients undergoing chemotherapy for breast cancer

  2020cites this paper
• Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer.

  2019cites this paper
• Risk Factors of Chemotherapy-Induced Neutropenia associated with FOLFOX, FOLFIRI, and FOLFOXIRI Regimens used in Patients with Advanced and Metastatic Colorectal Cancer

  2019cites this paper
• Neoadjuvant Chemotherapy Treatment Modifications in Ovarian Carcinoma: The Impact on Surgical Outcome and Progression-free Survival

  2019cites this paper
• The Effects of Ganglioside-Monosialic Acid in Taxane-induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.

  2019cites this paper
• Multiday corticosteroids in cancer chemotherapy delay the diagnosis of and antimicrobial administration for febrile neutropenia: a double-center retrospective study

  2019cites this paper
• Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis

  2019cites this paper
• Correction to: Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer

  2018cites this paper
• Neutropenia and first cycle of chemoradiotherapy: A retrospective analysis of 100 cancer patients

  2018cites this paper
• Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer

  2018cites this paper
• Managing Bone Marrow Toxicities

  2018cites this paper
• Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data.

  2017cites this paper
• Neutropenic complications in Chinese patients with breast cancer in a real-world setting

  2017cites this paper
• The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer – A Retrospective Study

  2017cites this paper
• Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions

  2017cites this paper
• Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

  2017cites this paper
• A systematic literature review of the efficacy, effectiveness, and safety of filgrastim

  2017cites this paper
• Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer

  2017cites this paper
• Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy

  2017influential citation
• A Phase III, Randomized, Double‐Blind, Placebo‐Controlled Trial of Pegfilgrastim in Patients Receiving First‐Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti‐VEGF Evaluation Study (PAVES)

  2017cites this paper
• Acceptability of the MD Anderson Symptom Inventory and qualitative analysis of barriers to palliative care services for rural and non-rural populations

  2017cites this paper
• Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea

  2016cites this paper
• Clinically Relevant Physical Benefits of Exercise Interventions in Breast Cancer Survivors

  2016cites this paper
• Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy

  2016cites this paper
• Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim

  2016cites this paper
• The effect of chemotherapy-induced anemia on dose reduction and dose delay

  2016cites this paper
• A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients

  2016cites this paper
• Impact of the automatic rounding-off function of the computerized physician order entry system on the ordering time and dose dispersion of chemotherapeutic drugs in regimens for hematologic malignancies

  2016cites this paper
• Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System

  2015cites this paper
• Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations

  2015cites this paper
• Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors

  2015cites this paper
• Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.

  2015cites this paper
• Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study.

  2015cites this paper
• Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.

  2014cites this paper
• Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.

  2014cites this paper
• Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings

  2014cites this paper
• Management of Breast Cancer Patients with Chemotherapy-Induced Neutropenia or Febrile Neutropenia

  2014cites this paper
• Granulocyte Colony-stimulating Factors Used in Clinical Practice: PoloNord Registry-Based Cohort Italian Study

  2014cites this paper
• Predicting chemotherapy-induced febrile neutropenia outcomes in adult cancer patients: an evidence-based prognostic model.

  2014cites this paper
• Procalcitonin as a marker of infection in febrile neutropenia: A systematic review

  2013cites this paper
• Relative dose intensity in early stage breast cancer chemotherapy: A retrospective analysis of incidence, risk factors and outcomes at a south‐west Sydney cancer clinic

  2013cites this paper
• Implementing an Evidence-Based Risk Assessment Tool to Predict Chemotherapy-Induced Neutropenia in Women With Breast Cancer

  2013cites this paper
• Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.

  2013cites this paper
• Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer.

  2012cites this paper
• Prognostic factors for risk stratification of adult cancer patients with chemotherapy‐induced febrile neutropenia: a systematic review and meta‐analysis

  2012cites this paper
• Chemotherapy operations planning and scheduling

  2012cites this paper
• Neutropenia Prediction Based on First-Cycle Blood Counts Using a FOS-3NN Classifier

  2012cites this paper
• Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer.

  2012cites this paper
• Supportive Care in Hemato-Oncology: A Review in Light of the Latest Guidelines

  2012cites this paper
• Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

  2012cites this paper
• Factors contributing to disparities in early breast cancer treatment

  2012cites this paper
• Costs Associated with Febrile Neutropenia in the US

  2012cites this paper
• erapies ambulatoires avec la prise en compte des protocoles de soins et des incertitudes.

  2012cites this paper
• Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

  2012cites this paper
• Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients

  2012cites this paper
• 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

  2011cites this paper
• Prognostic indicators predictive of chemotherapy‐induced febrile neutropenia outcomes in adult cancer patients: a systematic review

  2011cites this paper
• Hematologic Support of the Patient with Malignancy

  2011cites this paper
• Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.

  2011cites this paper
• The Patient Care Monitor-Neutropenia Index: development, reliability, and validity of a measure for chemotherapy-induced neutropenia.

  2011cites this paper
• Low rate of neutropenia and related events in patients with breast cancer receiving pegfilgrastim from the first cycle of chemotherapy in community practices

  2010cites this paper
• Risk of mortality in patients with cancer who experience febrile neutropenia

  2010cites this paper
• The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

  2010cites this paper
• Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.

  2009cites this paper
• Controlled application and scheduled removal of nanoparticle based chemotherapeutics (CARL) will reduce dose limiting adverse events in anticancer chemotherapy.

  2009cites this paper
• Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.

  2009cites this paper
• Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer.

  2009cites this paper
• Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy

  2009cites this paper
• Neutrophil count is not associated with infection episodes in breast cancer patients treated with anthracycline-based chemotherapy.

  2009cites this paper
• Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy

  2008cites this paper
• Neutropenia and Its Complications

  2008cites this paper
• Impact of neutropenia on delivering planned chemotherapy for solid tumours.

  2007cites this paper
• Intensidad de dosis recibida en el tratamiento quimioterápico del cáncer de mama

  2007cites this paper
• Multilevel modelling in the analysis of observational datasets in the health care setting

  2007cites this paper